Magnetoconductance anisotropy of a polymer thin film at the onset of metallicity

Thin films of poly(2,5-bis(3-dodecyl-2-yl)-thieno[3,2-b] thiophene) (C12-PBTTT) polymer under electrolyte gating and doping are investigated as model systems for organic thin films devices approaching the metallic side of a metal-insulator (M-I) transition. For the most doped samples, with an estimated density reaching 8 x 10(20) cm(-3) holes and a conductivity exceeding 1000 S cm(-1), a positive high-field magnetoconductance is found in a limited temperature range window and only when the field is perpendicular to the sample plane. This signature of weak localization, combined with indications of finite zero-temperature conductivity, allows us to identify delocalized metallic-like transport in these thin films, even though the conductivity decreases when cooling down the samples. (C) 2015 AIP Publishing LLC

Medical treatment of prolactinomas.

Prolactinomas, the most prevalent type of neuroendocrine disease, account for approximately 40% of all pituitary adenomas. The most important clinical problems associated with prolactinomas are hypogonadism, infertility and hyposexuality. In patients with macroprolactinomas, mass effects, including visual field defects, headaches and neurological disturbances, can also occur. The objectives of therapy are normalization of prolactin levels, to restore eugonadism, and reduction of tumor mass, both of which can be achieved in the majority of patients by treatment with dopamine agonists. Given their association with minimal morbidity, these drugs currently represent the mainstay of treatment for prolactinomas. Novel data indicate that these agents can be successfully withdrawn in a subset of patients after normalization of prolactin levels and tumor disappearance, which suggests the possibility that medical therapy may not be required throughout life. Nevertheless, multimodal therapy that involves surgery, radiotherapy or both may be necessary in some cases, such as patients who are resistant to the effects of dopamine agonists or for those with atypical prolactinomas. This Review reports on efficacy and safety of pharmacotherapy in patients with prolactinomas